CN109568593A - 一种叶酸受体介导、光激发光敏药物偶联物及其制备方法 - Google Patents
一种叶酸受体介导、光激发光敏药物偶联物及其制备方法 Download PDFInfo
- Publication number
- CN109568593A CN109568593A CN201710912938.4A CN201710912938A CN109568593A CN 109568593 A CN109568593 A CN 109568593A CN 201710912938 A CN201710912938 A CN 201710912938A CN 109568593 A CN109568593 A CN 109568593A
- Authority
- CN
- China
- Prior art keywords
- haematoporphyrin
- preparation
- folacin receptor
- folic acid
- peg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 title claims abstract description 68
- 239000011724 folic acid Substances 0.000 title claims abstract description 43
- 235000019152 folic acid Nutrition 0.000 title claims abstract description 43
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 229940079593 drug Drugs 0.000 title claims abstract description 31
- 102000005962 receptors Human genes 0.000 title claims abstract description 23
- 108020003175 receptors Proteins 0.000 title claims abstract description 23
- 229940064302 folacin Drugs 0.000 title claims abstract description 20
- 230000001404 mediated effect Effects 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 238000004020 luminiscence type Methods 0.000 title claims abstract description 8
- 230000001235 sensitizing effect Effects 0.000 title claims abstract description 8
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 claims abstract description 24
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960000304 folic acid Drugs 0.000 claims abstract description 23
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 7
- 229940068917 polyethylene glycols Drugs 0.000 claims abstract description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 238000007306 functionalization reaction Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 3
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 claims 1
- 230000008685 targeting Effects 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 abstract description 9
- 230000005284 excitation Effects 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 230000008878 coupling Effects 0.000 abstract description 2
- 238000010168 coupling process Methods 0.000 abstract description 2
- 238000005859 coupling reaction Methods 0.000 abstract description 2
- 230000012202 endocytosis Effects 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 abstract description 2
- 238000011938 amidation process Methods 0.000 abstract 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 abstract 1
- 229960003569 hematoporphyrin Drugs 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 32
- 206010028980 Neoplasm Diseases 0.000 description 29
- 201000011510 cancer Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 206010034972 Photosensitivity reaction Diseases 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 208000007578 phototoxic dermatitis Diseases 0.000 description 5
- 231100000018 phototoxicity Toxicity 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000007086 side reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- RKCAIXNGYQCCAL-UHFFFAOYSA-N porphin Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 RKCAIXNGYQCCAL-UHFFFAOYSA-N 0.000 description 2
- 150000004032 porphyrins Chemical class 0.000 description 2
- 230000003307 reticuloendothelial effect Effects 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- -1 α-ethoxy Chemical group 0.000 description 2
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000005950 photosensitized reaction Methods 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/008—Two-Photon or Multi-Photon PDT, e.g. with upconverting dyes or photosensitisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0036—Porphyrins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明属于高分子药物技术领域，具体涉及一种叶酸受体介导、光激发光敏药物偶联物及其制备方法。首先将叶酸与氨基聚乙二醇进行酰胺化反应，然后与血卟啉HPD进行酰胺化反应，获得具有叶酸受体靶向光激发血卟啉基团的聚乙二醇柔性链偶联。本发明制备所得的偶联物，能够通过叶酸受体介导靶向肿瘤细胞，经过内吞进入细胞，加快血卟啉肿瘤细胞内的积蓄，经特定波长紫光或红光照射，可以进行精准诊断和治疗；同时本发明为制备靶向血卟啉荧光分子药物偶联物提供了一种简单而有效的途径。
Description
技术领域
本发明属于高分子药物技术领域，具体涉及一种叶酸受体介导，光激发光敏 药物偶联物及其制备方法。
背景技术
光激发的血卟啉光敏药物是癌症诊断和治疗的一类新药，通过紫光照射可激 发荧光，通过荧光检测，可以用癌症早期诊断。它也可以通过光动力学疗法对癌 症进行治疗，且其治疗优于传统的手术、放疗和化疗三大治疗肿瘤手段许多，它 对癌组织都具有非常强的选择性，对正常组织的损伤很小。原因是这种血卟啉药 物注入体内1h后，各组织中放射性含量达高峰，组织分布顺序为肺＞肝＞肾＞血＞ 胃＞肠＞脾＞心＞肌肉＞胸腺＞脑＞骨，肿瘤中的含量为以上12种组织中的第89位； 到72h，肿瘤组织的含量上升到第5位。注射本品5h后，总排泄量占注射量的 73.29％，d 11为91％。由此见可，这药物注入人体后到达肿瘤中不是最高的， 通过72h的代谢排泄后，由于肿瘤组织对血卟啉光敏药物亲合力高，有潴留作用， 才能形成肿瘤的贮存高于周边正常组织，在诊断和治疗中才能起到选择性治疗作 用，而在这光敏药物在形成肿瘤组织浓度比正常组织高，是经过48h＝72h的漫长 的排泄过程，在这过程中正常组织的药物含量是非常高，对人体产生光毒性自然 是大的，为此通过接受治疗患者要在暗室中避光一个月时间，极其不方便。
本发明就针对这类药物在癌症诊断和治疗所存在问题，采用受体靶向策略， 发明出一种能快速在特定肿瘤组织中达到有效光敏药物诊断及治疗浓度的受体 靶向新型偶联物，将把光激发的光敏药物与叶酸受体偶联，一旦注入人体内，就 能与FR特异性结合，选择性浓集于FR表达丰富的组织，通常来说许多恶性肿瘤 都存在FR丰富表达。在这FR在靶组织和非靶组织分布的显著性差异，FR介导 的偶联物可获得靶组织与正常组织高对比度的浓度差异，故能对病变进行诊断、 定位及治疗效。由此看来本发明的受体靶向新型偶联物能为改变以往在癌症诊断 和治疗中所使用血卟啉类光敏药物，利用效率不高，有80％没能利用以上排泄 体外的缺陷，药物能高效快速投放在肿瘤中，正常组织残留小，光毒副作用小，在治疗时中也无需暗室进行避光。因此这种叶酸受体介导靶向、光(紫光、红双 光子)激发的光敏药物偶联物，在临床应用中将会具有广泛发展前景。
目前尚未见到此类叶酸受体介导靶向光敏药物偶联物的文献报道。
发明内容
本发明的一个目的是提供一种叶酸受体介导靶向、光(紫光、红光)激发的 光敏药物偶联物。
本发明的另一个目的是提供所述偶联物的制备方法。
本发明的目的通过一下技术方案来予以实现：
提供一种叶酸受体介导、光激发的光敏药物偶联物，其结构通式：
其中：FA为叶酸，PEG为分子量范围500～5000Da的聚乙二醇。
所述一种叶酸受体介导、光激发光敏药物偶联物的制备步骤：
(1)将叶酸与双端氨基聚乙二醇反应，得到叶酸功能化的单端氨基聚乙二醇；
(2)将叶酸功能化的单端氨基聚乙二醇与反应得到主链末端含有血卟啉的聚乙二醇；
在步骤(1)中，首先在无水二甲亚砜溶液中，采用二环己基碳二亚胺(DCC)、 N-羟基琥珀酰亚胺(NHS)和三乙胺(TEA)组合催化剂，然后将叶酸(FA)、双 端氨基聚乙二醇NH2-PEG-NH2、DCC、NHS和TEA，按摩尔用量为1∶1∶1.5∶1.5∶5 的配比，在室温下搅拌反应10～20小时。
在步骤(2)中，将FA-PEG-NH2溶在N，N-二甲基酰胺(DMF)中，加入血 卟啉(1，3，5，8-四甲基-2，4-二(α-羟乙基)卟酚-6，7-二丙酸)，然后在EDC、NHS组合催化中进行反应，它们的摩尔用量为1∶1∶1.5∶1.5，反应中在室温下进 行搅拌，反应时间为10～20小时。
制备得到抗肿瘤药物偶联物的主要特点：(1)在叶酸的介导下，偶联物有选 择性第富集于肿瘤细胞表面，而在正常细胞表面上较少存在，并通过受体介导内 吞作用进入细胞；(2)偶联物中链接有聚乙二醇柔性链，科技减少与网状内皮细 胞膜的亲和性没，从而避免网状内皮细胞的吞噬，延长药物在血液中的循环时间， 增强被动靶向肿瘤组织效应；(3)此偶联物不仅可以响应紫光，还可以发生红双 光子作用下激发，释放出荧光发现恶性肿瘤，或在红光照射下引发化学反应释放 单态氧毒杀肿瘤细胞起到治疗效果，而叶酸和聚乙二醇是无毒无害的，尤其是在 治疗红光的使用，因为长波长红光对组织细胞损伤较小，且能够增加对组织的穿 透深度，有无比优越。
发明有益效果
本发明提供了简单易行的偶联物制备方法，是基于含有光致断裂基团的聚乙 二醇为链接剂，与细胞特异性配体叶酸等相连，成功合成携带有光致断裂结构和 对肿瘤细胞上的叶酸受体具有高亲和力的靶向光激发光敏药物，自1986年科学 家发现叶酸(FA)是由受体介导的内吞途径进入细胞以来，人们开始对FA作为靶 向载体进行深入研究。现已证实在卵巢癌、子宫内膜癌、间皮组织癌、肾癌、头 颈部肿瘤、肺癌、乳腺癌、结直肠癌等恶性上皮组织来源肿瘤、关节炎部位有过 表达的叶酸受体(FR)。这样本发明的叶酸受体介导、光激发光敏药物偶联物会 主动靶向在特定肿瘤组织细胞表面，并能够在外界环境特定波长光刺激下释放出 荧光用于肿瘤检测。在特定波长激发下发生化学反应产生单态氧毒死癌细胞达到 精准治疗效果，具有良好的医药领域应用推广价值。
附图说明
图1为本发明反应式。
具体实施方式
以下结合实施例来进一步解释本发明，但实施例并不对本发明作任何形式的 限制。
实施例1叶酸-聚乙二醇-血卟啉偶联物的制备，叶酸-聚乙二醇-光敏偶联剂的合成。
1)叶酸功能话的聚乙二醇的合成。
称取双端氨基聚乙二醇(NH2-PEG-NH2，M＝3200Da)640mg溶解在10ml无水 DMSO中，加入2ml溶有叶酸FA和NHS的DMSO溶液，然后依次加入DCC、TEA(各 物质的摩尔用量NH2-PEG-NH2∶FA∶NHS∶DCC∶TEA＝ 1∶1∶1.5∶1.5∶5)，在氮气保护下，室温搅拌、避光反应12h，将反应混合物用20ml 去离子水稀释、在500rpm下离心，除去副产物二环己基脲，再加入10ml丙酮以 除去未反应的叶酸，将上清液放入截留分子量为3000Da的透析管中，用去离子 水稀释48h，冷冻干燥，得到FA-PEG-NH2。
2)连有光敏基团聚乙二醇的合成。
600mg FA-PEG-NH2溶于20ml DMF中，然后加入血卟啉(1，3，5，8-四甲基-2，4- 二(α-羟乙基)卟酚-6，7-二丙酸)、EDC、NHS(摩尔比为 FA-PEG-NH2∶HPD∶EDC∶NHS＝1∶1∶1.5∶5)通入氮气，室温搅拌反应15h，加入20ml 去离子水稀释、在500rpm下离心，将上清液转入透析管中用去离子水透析48h 后，冷冻干燥，得到FA-PEG-HPD。
实施例2光毒性副反应及在肿瘤组织中的靶向性效果观察。
1)光毒性副反应实验
以血卟啉注射液(重庆市华鼎现在生物制药有限责任公司)为对比例。取 ICR小鼠20只，雌雄各半，随机分为2组，每组10只。各组小鼠经尾部静脉给 予实施例和对比例药物(按照血卟啉计算给药剂量为6.26×10-2g·Kg-1·d-1)。 给药前小鼠背部去毛，去毛面积为2cm×2cm。给药后1h，将两组小鼠置于5500K 色温光源(近似室外午后大阳光)3500LX光照条件下照射20min，以小鼠背部皮 肤为主要观察区域，分别于不同的时间观察比较实施例和对比例光毒性副反应。 使用405nm半导体激光，以50mw/cm2的功率照射，观察发射荧光特征的表现。观 察结果见表1。
表1组药物中血卟啉对小鼠光毒性副反应的影响以及荧光特征表现
从表1以看出，将血卟啉用叶酸偶联后，明显降低血卟啉的光敏毒性。而从荧 光特征观察引起光毒反应的确来自于血卟啉药物的光敏反应。
2)药物滞留量实验
以血卟啉注册液(重庆市华鼎现代生物制药有限责任公司)为对比例，比较 实施例和对比例在肿瘤组织中的靶向性及给药24h在肿瘤组织中的滞留量。
将HePG-2细胞接种子ICR小鼠右前肢皮下，建立小鼠肝脏肿瘤模型，分别 将对比例和实施例样品经小鼠尾静脉给药后，不同时间点(0.05h、0.25h、0.5h、 1h、2h、4h、8h、12h、24h)将小鼠处死，取肿瘤块，用HPLC分析肿瘤组织中 血卟啉含量，计算各组药物中血卟啉的相对靶向率及24h在肿瘤组织的滞留量。 结果见表2。
表2组药物中血卟啉在肿瘤组织的靶向性和24h滞留量
从表2可以看出，将血卟啉用叶酸偶联后，明显提高血卟啉在肿瘤组织的靶 向性和滞留量，延长血卟啉在肿瘤组织的滞留时间。
从以上的实验观察可以看出本发明采用受体靶向策略，制成的叶酸受体介 导、光激发光敏药物偶联物与普通血卟啉注射液相比较，正常组织含量少，靶向 特征明显，大大提高血卟啉体内恶性肿瘤中的含量。
以上所述仅是本发明的一种优选实施方式，对于本技术领域的普通技术人员 来说，在不脱离本发明原理前提下，还可以做出若干的变换和改进，这些变换和 改进也应视为本发明的保护范围。
Claims (4)
1.一种叶酸受体介导、光激发光敏药物偶联物，其特征在于其结构式：
其中：FA为叶酸，PEG为分子量范围500～5000Da的聚乙二醇。
2.权利要求1所述一种叶酸受体介导、光激发光敏药物偶联物的制备方法，其特征在于包括以下步骤：
(1)将叶酸与双端氨基聚乙二醇反应，得到叶酸功能化的单端氨基聚乙二醇；
(2)将叶酸功能化的单端氨基聚乙二醇与血卟啉反应得到主链末端含有血卟啉光敏基团的聚乙二醇。
3.根据权利要求2所述的制备方法，其特征在于步骤(1)中，首先在二甲亚砜溶液中，采用二环已基碳二亚胺(DCC)、N-羟基琥珀酰亚胺(NHS)和三乙胺(TEA)组合催化剂，然后将叶酸(FA)、双端氨基聚乙二醇NH2-PEG-NH2、DCC、NHS和TEA，按摩尔用量为1∶1∶1.5∶1.5∶5的配比，在室温下搅拌反应10～20小时。
4.根据权利要求2所述的制备方法，其特征在于步骤(2)中，将FA-PEG-NH2溶在N，N-二甲基酰胺(DMF)中，加入血卟啉，然后在EDC、NHS组合催化中进行反应，它们的摩尔用量为1∶1∶1.5∶1.5，反应中在室温下进行搅拌，反应时间为10～20小时。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710912938.4A CN109568593A (zh) | 2017-09-28 | 2017-09-28 | 一种叶酸受体介导、光激发光敏药物偶联物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710912938.4A CN109568593A (zh) | 2017-09-28 | 2017-09-28 | 一种叶酸受体介导、光激发光敏药物偶联物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109568593A true CN109568593A (zh) | 2019-04-05 |
Family
ID=65919380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710912938.4A Withdrawn CN109568593A (zh) | 2017-09-28 | 2017-09-28 | 一种叶酸受体介导、光激发光敏药物偶联物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109568593A (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053247A1 (en) * | 2005-10-07 | 2009-02-26 | Photobiotics Limited | Biological materials and uses thereof |
| US20100297017A1 (en) * | 2008-01-31 | 2010-11-25 | Mark Savellano | Method for Synthesizing and Using Pegylated Peptide-Photoactive Chromophore Conjugates and Micellular Formulations Thereof |
| CN103768614A (zh) * | 2013-11-08 | 2014-05-07 | 盐城工学院 | 一种叶酸受体介导、光响应抗肿瘤药物偶联物及其制备方法 |
| CN106924732A (zh) * | 2017-03-09 | 2017-07-07 | 南京理工大学 | 一种超声治疗用肿瘤靶向型血卟啉注射剂及其制备方法 |
-
2017
- 2017-09-28 CN CN201710912938.4A patent/CN109568593A/zh not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090053247A1 (en) * | 2005-10-07 | 2009-02-26 | Photobiotics Limited | Biological materials and uses thereof |
| US20100297017A1 (en) * | 2008-01-31 | 2010-11-25 | Mark Savellano | Method for Synthesizing and Using Pegylated Peptide-Photoactive Chromophore Conjugates and Micellular Formulations Thereof |
| CN103768614A (zh) * | 2013-11-08 | 2014-05-07 | 盐城工学院 | 一种叶酸受体介导、光响应抗肿瘤药物偶联物及其制备方法 |
| CN106924732A (zh) * | 2017-03-09 | 2017-07-07 | 南京理工大学 | 一种超声治疗用肿瘤靶向型血卟啉注射剂及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shen et al. | Recent progress in tumor photodynamic immunotherapy | |
| Ai et al. | Enhanced cellular ablation by attenuating hypoxia status and reprogramming tumor-associated macrophages via NIR light-responsive upconversion nanocrystals | |
| US11235000B2 (en) | Calcium peroxides nanoparticles as adjuvant therapy | |
| Simelane et al. | Photodynamic diagnosis and photodynamic therapy of colorectal cancer in vitro and in vivo | |
| Nosrati et al. | Prodrug polymeric nanoconjugates encapsulating gold nanoparticles for enhanced X‐Ray radiation therapy in breast cancer | |
| CN109776380A (zh) | Ir780双靶向近红外荧光探针制备及肿瘤诊疗中应用 | |
| Xu et al. | Photodynamic diagnosis and therapy for peritoneal carcinomatosis: emerging perspectives | |
| CN107875384A (zh) | 一种包载光敏剂的肿瘤靶向治疗用药物递送系统 | |
| CN110101685A (zh) | 一种仿生纳米药物、其制备方法及应用 | |
| CN111249461A (zh) | 藻蓝蛋白-二氢卟酚e6共价纳米颗粒的制备及其应用 | |
| CN105126121B (zh) | 一种靶向金银合金纳米笼的药物递送系统的制备方法及应用 | |
| CN109464676B (zh) | 一种壳寡糖光敏靶向纳米粒的制备方法及产品 | |
| CN103539799B (zh) | 一种水溶性氨基多羧酸修饰酞菁化合物的制备方法和用途 | |
| CN113384709B (zh) | 一种葡聚糖-原卟啉前药纳米胶束的制备和应用 | |
| CN107337685B (zh) | 叶酸靶向Pyro光敏的合成和应用 | |
| CN106890341A (zh) | 基于化学交联的光疗纳米制剂及其制备方法和应用 | |
| CN1531442A (zh) | 用作光敏剂和声敏剂的苝醌 | |
| CN109568593A (zh) | 一种叶酸受体介导、光激发光敏药物偶联物及其制备方法 | |
| CN102363619A (zh) | 水溶性原卟啉化合物及制备方法及用途 | |
| CN113616809B (zh) | 超分子有机框架材料在清除光动力治疗残留药物中的应用 | |
| CN106606783A (zh) | 一种靶向共递释光敏剂与化疗药物的药物递释系统 | |
| CN113384698A (zh) | 一种协同化疗/声-光动力治疗的自组装纳米药物及其应用 | |
| KR101847486B1 (ko) | 친수성 기 및 소수성 기를 갖는 포르피린 유도체 및 이의 제조방법 | |
| CN111714483A (zh) | 半胱氨酸衍生物作为辐射防护剂的应用 | |
| CN102961755A (zh) | 肿瘤治疗用配体功能化超分子纳米给药系统 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| DD01 | Delivery of document by public notice |
Addressee: Ye Yanming Document name: Notification of Publication of the Application for Invention |
|
| DD01 | Delivery of document by public notice | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20200904 Address after: No. 162, Renmin South Road, Taicang, Suzhou, Jiangsu 215499 Applicant after: YANQUAN BIOLOGY TECHNOLOGY (TAICANG) Co.,Ltd. Address before: 200233 room 585, No. 1404, Xuhui District, Shanghai, Guilin Road Applicant before: Ye Yanming |
|
| TA01 | Transfer of patent application right | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190405 |
|
| WW01 | Invention patent application withdrawn after publication |